Rainier Therapeutics
San Leandro
About Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $89.0M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2018)
- Website: rainierrx.com
- Phone: +1-510-878-2486
Industries & Categories
Biopharma, Biotechnology, Developer Platform, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rainier-therapeutics-111546 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.